Differences in Peptic Ulcer Between the East and the West

Gastroenterology Clinics of North America

Volumn 38, Issue 2, 2009, Pages 363-379

  Leong, Rupert W ^a,b  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

Author keywords

Asia; Caucasian; Epidemiology; Ethnicity; Management; Polymorphism; Race; Ulcer

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; CLARITHROMYCIN; DRINKING WATER; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN;

ANTIBIOTIC RESISTANCE; ASIA; AUSTRALIA; BANGLADESH; BULGARIA; CANADA; CHINA; CZECH REPUBLIC; DIET; DIGESTIVE SYSTEM PERFORATION; DISEASE PREDISPOSITION; DRUG CLEARANCE; DRUG METABOLISM; ESTONIA; GASTROSCOPY; GENETICS; GEOGRAPHICAL VARIATION (SPECIES); GERMANY; HELICOBACTER INFECTION; HONG KONG; HUMAN; ICELAND; INDONESIA; JAPAN; LOW DRUG DOSE; MALAYSIA; MORTALITY; NETHERLANDS; NONHUMAN; PEPTIC ULCER; PEPTIC ULCER BLEEDING; RACE DIFFERENCE; RADIOLOGY; RECURRENT DISEASE; REVIEW; RISK FACTOR; SERBIA; SEX DIFFERENCE; SINGAPORE; SOUTH KOREA; SWEDEN; SWITZERLAND; TAIWAN; UNITED KINGDOM; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ASPIRIN; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS; RISK FACTORS; TREATMENT OUTCOME; WORLD HEALTH;

EID: 65549091382     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2009.03.010     Document Type: Review

References (98)

1. Leong R.W.L., and Chan F.K.L. Duodenal ulcer. In: Johnson L.R. (Ed). Encyclopedia of gastroenterology. 1st edition (2004), Academic Press, Memphis (USA) 645-652
2. Aro P., Storskrubb T., Ronkainen J., et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol 163 11 (2006) 1025-1034
3. Wong B.C., Lam S.K., Wong W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291 2 (2004) 187-194
4. Lam S.K. Differences in peptic ulcer between East and West. Baillieres Best Pract Res Clin Gastroenterol 14 1 (2000) 41-52
5. Jang H.J., Choi M.H., Shin W.G., et al. Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi-center study. Dig Dis Sci 53 6 (2008) 1527-1531
6. Wong S.N., Sollano J.D., Chan M.M., et al. Changing trends in peptic ulcer prevalence in a tertiary care setting in the Philippines: a seven-year study. J Gastroenterol Hepatol 20 4 (2005) 628-632
7. Guo Q., and Zhan L. [Analysis of 136 children with gastrointestinal hemorrhage]. Hunan Yi Ke Da Xue Xue Bao 26 (2001) 566-568 [Chinese]
8. Houben C.H., Chiu P.W., Lau J.Y., et al. Duodenal ulcers dominate acute upper gastrointestinal tract bleeding in childhood: a 10-year experience from Hong Kong. J Dig Dis 9 4 (2008) 199-203
9. Xia H.H., Phung N., Kalantar J.S., et al. Demographic and endoscopic characteristics of patients with Helicobacter pylori positive and negative peptic ulcer disease. Med J Aust 173 10 (2000) 515-519
10. Langman M.J.S. Aetiology of peptic ulcer. In: Murphy M., Rawlins M.D., and Venebles C.W. (Eds). Diseases of the gut and pancreas (1987), Blackwell, Oxford (UK) 268-281
11. Elashoff J.D., and Grossman M.I. Trends in hospital admissions and death rates for peptic ulcer in the United States from 1970 to 1978. Gastroenterology 78 2 (1980) 280-285
12. Preshaw R.M. Sex differences in morbidity and mortality from peptic ulcer in Canada, 1950-1981. Clin Invest Med 8 1 (1985) 62-67
13. Bardhan K.D., and Royston C. Time, change and peptic ulcer disease in Rotherham, UK. Dig Liver Dis 40 7 (2008) 540-546 Epub 2008 Apr 14
14. Higham J., Kang J.Y., and Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 50 4 (2002) 460-464
15. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 132 7 (2007) 2320-2327 Epub 2007 Apr 14
16. Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 102 5 (2007) 1101-1107
17. Tango T., and Kurashina S. Age, period and cohort analysis of trends in mortality from major diseases in Japan, 1955 to 1979: peculiarity of the cohort born in the early Showa Era. Stat Med 6 6 (1987) 709-726
18. Graham D.Y. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol 6 (1991) 105-113
19. Cheng F.C.Y., Lam S.K., and Ong G.B. Maximum acid output to graded doses of pentagastrin and its relation to parietal cell mass in Chinese patients with duodenal ulcer. Gut 18 (1977) 827-832
20. Card W.I., and Marks I.N. The relationship between the acid output of the stomach following 'maximal' histamine stimulation and the parietal cell mass. Clin Sci 19 (1960) 147-163
21. Lam S.K., Hasan M., Sircus W., et al. Comparison of maximal acid output and gastrin response to meals in Chinese and Scottish normal and duodenal ulcer subjects. Gut 21 4 (1980) 324-328
22. Mitchell H.M., Li Y.Y., Hu P.J., et al. Epidemiology of Helicobacter pylori in southern China: identification of early childhood as the critical period for acquisition. J Infect Dis 166 (1992) 149-153
23. Pounder R.E., and Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 9 Suppl 2 (1995) 33-39
24. Brown L.M. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 22 (2000) 283-297
25. Ahmed K.S., Khan A.A., Ahmed I., et al. Impact of household hygiene and water source on the prevalence and transmission of Helicobacter pylori: a South Indian perspective. Singapore Med J 48 6 (2007) 543-549
26. Lee I., Lee H., Kim M., et al. Ethnic difference of Helicobacter pylori gastritis: Korean and Japanese gastritis is characterized by male- and antrum-predominant acute foveolitis in comparison with American gastritis. World J Gastroenterol 11 1 (2005) 94-98
27. El-Zimaity H.M.T., Gutierrez O., Kim J.G., et al. Geographic differences in the distribution of intestinal metaplasia in duodenal ulcer patients. Am J Gastroenterol 96 3 (2001) 666-672
28. Goh K.L., and Parasakthi N. The racial cohort phenomenon: seroepidemiology of Helicobacter pylori infection in a multiracial South-East Asian country. Eur J Gastroenterol Hepatol 13 2 (2001) 177-183
29. Saragih J.B., Akbar N., Syam A.F., et al. Incidence of Helicobacter pylori infection and gastric cancer: an 8-year hospital based study. Acta Med Indones 39 2 (2007) 79-81
30. Uyub A.M., Raj S.M., Visvanathan R., et al. Helicobacter pylori infection in north-eastern Peninsular Malaysia - evidence for an unusually low prevalence, Scand. J Gastroenterol 29 (1994) 209-213
31. Graham D.Y., Yamaoka Y., and Malaty H.M. Thoughts about populations with unexpected low prevalences of Helicobacter pylori infection. Trans R Soc Trop Med Hyg 101 9 (2007) 849-851
32. Fujisawa T., Kumagai T., Akamatsu T., et al. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis a virus over the last 20 years in Japan. Am J Gastroenterol 94 (1999) 2094-2099
33. Lee S.Y., Park H.S., Yu S.K., et al. Decreasing prevalence of Helicobacter pylori infection: a 9-year observational study. Hepatogastroenterology 54 74 (2007) 630-633
34. Chen J., Bu X.L., Wang Q.Y., et al. Decreasing seroprevalence of Helicobacter pylori infection during 1993-2003 in Guangzhou, southern China. Helicobacter 12 2 (2007) 164-169
35. Ma J.L., You W.C., Gail M.H., et al. Helicobacter pylori infection and mode of transmission in a population at high risk of stomach cancer. Int J Epidemiol 27 4 (1998) 570-573
36. Zhang L., Blot W.J., You W.C., et al. Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 5 (1996) 627-630
37. Wong K.K.Y., Chung P.H.Y., Lan L.C.L., et al. Trends in the prevalence of Helicobacter pylori in symptomatic children in the era of eradication. J Pediatr Surg 40 (2005) 1844-1847
38. Wong B.P.Y., Chao N.S.Y., Leung M.W.Y., et al. Complications of peptic ulcer disease in children and adolescents: minimally invasive treatments offer feasible surgical options. J Pediatr Surg 41 (2006) 2073-2075
39. Gruber D., Pohl D., Vavricka S., et al. Swiss tertiary care center experience challenges the age-cohort effect in Helicobacter pylori infection. J Gastrointestin Liver Dis 17 4 (2008) 373-377
40. Moujaber T., MacIntyre C.R., Backhouse J., et al. The seroepidemiology of Helicobacter pylori infection in Australia. Int J Infect Dis 12 5 (2008) 500-504 Epub 2008 Apr 8
41. Fujimoto Y., Furusyo N., Toyoda K., et al. Intrafamilial transmission of Helicobacter pylori among the population of endemic areas in Japan. Helicobacter 12 2 (2007) 170-176
42. Lin D.B., Lin J.B., Chen C.Y., et al. Seroprevalence of Helicobacter pylori infection among schoolchildren and teachers in Taiwan. Helicobacter 12 3 (2007) 258-264
43. Okuda M., Miyashiro E., Booka M., et al. Helicobacter pylori colonization in the first 3 years of life in Japanese children. Helicobacter 12 4 (2007) 324-327
44. Yim J.Y., Kim N., Choi S.H., et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 12 4 (2007) 333-340
45. Shi R., Xu S., Zhang H., et al. Prevalence and risk factors for Helicobacter pylori infection in Chinese populations. Helicobacter 13 2 (2008) 157-165
46. Tam Y.H., Yeung C.K., Lee K.H., et al. A population-based study of Helicobacter pylori infection in Chinese children resident in Hong Kong: prevalence and potential risk factors. Helicobacter 13 3 (2008) 219-224
47. Yanaoka K., Oka M., Yoshimura N., et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer 123 4 (2008) 917-926
48. Bhuiyan T.R., Qadri F., Saha A., et al. Infection by Helicobacter pylori in Bangladeshi children from birth to two years: relation to blood group, nutritional status, and seasonality. Pediatr Infect Dis J 28 (2009) 79-85
49. Mourad-Baars P.E., Verspaget H.W., Mertens B.J., et al. Low prevalence of Helicobacter pylori infection in young children in the Netherlands. Eur J Gastroenterol Hepatol 19 3 (2007) 213-216
50. Dinić M., Tasić G., Stanković-Dordević D., et al. Serum anti-Helicobacter pylori IgA and IgG antibodies in asymptomatic children in Serbia. Scand J Infect Dis 39 4 (2007) 303-307
51. Boyanova L., Lazarova E., Jelev C., et al. Helicobacter pylori and Helicobacter heilmannii in untreated Bulgarian children over a period of 10 years. J Med Microbiol 56 Pt 8 (2007) 1081-1085
52. Thjodleifsson B., Asbjörnsdottir H., Sigurjonsdottir R.B., et al. Seroprevalence of Helicobacter pylori and cagA antibodies in Iceland, Estonia and Sweden. Scand J Infect Dis 39 8 (2007) 683-689
53. Naja F., Kreiger N., and Sullivan T. Helicobacter pylori infection in Ontario: prevalence and risk factors. Can J Gastroenterol 21 8 (2007) 501-506
54. Weck M.N., Stegmaier C., Rothenbacher D., et al. Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany. Aliment Pharmacol Ther 26 6 (2007) 879-887
55. Sterzl I., Hrdá P., Matucha P., et al. Anti-Helicobacter pylori, anti-thyroid peroxidase, anti-thyroglobulin and anti-gastric parietal cells antibodies in Czech population. Physiol Res 57 Suppl 1 (2008) S135-S141
56. Segal I., Otley A., Issenman R., et al. Low prevalence of Helicobacter pylori infection in Canadian children: a cross-sectional analysis. Can J Gastroenterol 22 5 (2008) 485-489
57. Monno R., Volpe A., Basho M., et al. Helicobacter pylori seroprevalence in selected groups of Albanian volunteers. Infection 36 4 (2008) 345-350 Epub 2008 Jun 20
58. Rejchrt S., Koupil I., Kopácová M., et al. European society for primary care gastroenterology. Prevalence and sociodemographic determinants of uninvestigated dyspepsia in the Czech Republic. Eur J Gastroenterol Hepatol 20 9 (2008) 898-905
59. Leong R.W.L., and Chan F.K.L. Drug-induced side effects affecting the gastrointestinal tract. Expert Opin Drug Saf 5 (2006) 585-592
60. Shiokawa Y., Nobunaga M., Saito T., et al. [Epidemiology study on upper gastrointestinal lesions induced by non-steroidal anti-inflammatory drugs]. Ryumachi 31 1 (1991) 96-111 [Japanese]
61. Larkai E.N., Smith J.L., Lidsky M.D., et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82 11 (1987) 1153-1158
62. Hippisley-Cox J., Coupland C., and Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331 7528 (2005) 1310-1316
63. Sakamoto C., Sugano K., Ota S., et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 62 9 (2006) 765-772
64. Shiotani A., Kamada T., and Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol 43 8 (2008) 581-588
65. Ishikawa S., Inaba T., Mizuno M., et al. Incidence of serious upper gastrointestinal bleeding in patients taking non-steroidal anti-inflammatory drugs in Japan. Acta Med Okayama 62 1 (2008) 29-36
66. Pilotto A., Seripa D., Franceschi M., et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 133 2 (2007) 465-471
67. Manuel D., Cutler A., Goldstein J., et al. Decreasing prevalence combined with increasing eradication of Helicobacter pylori infection in the United States has not resulted in fewer hospital admissions for peptic ulcer disease-related complications. Aliment Pharmacol Ther 25 12 (2007) 1423-1427
68. Huang J.Q., Sridhar S., and Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (2002) 14-22
69. Genta R.M., Gürer I.E., and Graham D.Y. Geographical pathology of Helicobacter pylori infection: is there more than one gastritis?. Ann Med 27 5 (1995) 595-599
70. Ciociola A.A., McSorley D.J., Turner K., et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 94 (1999) 1834-1840
71. Tokudome S., Ando R., Ghadimi R., et al. Are there any real Helicobacter pylori infection-negative gastric cancers in Asia?. Asian Pac J Cancer Prev 8 3 (2007) 462-463
72. Chan H.L.Y., Wu J.C.W., Chan F.K.L., et al. Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI Bleeding? A prospective study of 977 patients. Gastrointest Endosc 53 (2001) 438-442
73. Hung L.C., Ching J.Y., Sung J.J., et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers. A prospective cohort study. Gastroenterology 129 (2005) 1845-1850
74. Tovey F.I., Hobsley M., Kaushik S.P., et al. Duodenal gastric metaplasia and Helicobacter pylori infection in high and low duodenal ulcer-prevalent areas in India. J Gastroenterol Hepatol 19 5 (2004) 497-505
75. Paul Jayaraj A., Tovey F.I., and Hobsley M. Duodenal ulcer prevalence: research into the nature of possible protective dietary lipids. Phytother Res 17 4 (2003) 391-398
76. Wong B.C., Ching C.K., Lam S.K., et al. Differential north to south gastric cancer-duodenal ulcer gradient in China. China Ulcer Study Group. J Gastroenterol Hepatol 13 10 (1998) 1050-1057
77. Elmståhl S., Svensson U., and Berglund G. Fermented milk products are associated to ulcer disease. Results from a cross-sectional population study. Eur J Clin Nutr 52 9 (1998) 668-674
78. Kang J.Y., Yeoh K.G., Chia H.P., et al. Chili-protective factor against peptic ulcer?. Dig Dis Sci 40 3 (1995) 576-579
79. Malaty H.M., Graham D.Y., Isaksson I., et al. Are genetic influences on peptic ulcer dependent or independent of genetic influences for Helicobacter pylori infection?. Arch Intern Med 160 1 (2000) 105-109
80. Kaushik S.P., and Vu C. Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin: testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication. Aust N Z J Med 30 2 (2000) 231-235
81. Kwok A., Lam T., Katelaris P., et al. Helicobacter pylori eradication therapy: indications, efficacy and safety. Expert Opin Drug Saf 7 3 (2008) 271-281
82. Niv Y., and Hazazi R. Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter 13 1 (2008) 56-61
83. Chisholm S.A., Teare E.L., Davies K., et al. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005). Euro Surveill 12 7 (2007) E3-E4
84. Kalach N., Serhal L., Asmar E., et al. Helicobacter pylori primary resistant strains over 11 years in French children. Diagn Microbiol Infect Dis 59 2 (2007) 217-222
85. De Francesco V., Margiotta M., Zullo A., et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 59 4 (2007) 783-785 Epub 2007 Feb 28
86. Kobayashi I., Murakami K., Kato M., et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 45 12 (2007) 4006-4010 Epub 2007 Oct 17
87. Hu C.T., Wu C.C., Lin C.Y., et al. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J Gastroenterol Hepatol 22 5 (2007) 720-723
88. Van der Poorten D., and Katelaris P.H. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 26 11-12 (2007) 1537-1542
89. Furuta T., Ohashi K., Kamata T., et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129 12 (1998) 1027-1030
90. Andersson T., Regårdh C.G., Lou Y.C., et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2 1 (1992) 25-31
91. Ishizaki T., Sohn D., Kobayashi K., et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 16 2 (1994) 214-215
92. Daneshmend T.K., Hawkey C.J., Langman M.J., et al. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 304 (1992) 143-147
93. Schaffalitzky de Muckadell O.B., Havelund T., Harling H., et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol 32 (1997) 320-327
94. Lau J.Y., Sung J.J., Lee K.K., et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 343 (2000) 310-316
95. Khuroo M.S., Yattoo G.N., Javid G., et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 336 (1997) 1054-1058
96. Javid G., Masoodi I., Zargar S.A., et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 111 (2001) 280-284
97. Oh J.H., Choi M.G., Dong M.S., et al. Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients. J Gastroenterol Hepatol 22 9 (2007) 1429-1434 Epub 2007 Jul 20
98. Nakashima S., Arai S., Mizuno Y., et al. A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 21 Suppl 2 (2005) 60-66